ATLANTA—CareONE Concierge has announced the launch of a new research study to evaluate an innovative wearable device aimed at addressing cognitive symptoms associated with Alzheimer's-related dementia, and it is now accepting applicants for the study. The study will utilize the NeuroEM Therapeutics' TEMT-RF cap, a non-invasive device that has received breakthrough device designation from the U.S. Food and Drug Administration (FDA).
Alzheimer's disease is a growing global health crisis, affecting nearly 7 million Americans and is projected to impact nearly 13 million by 2050. Despite decades of research, treatment options remain limited, with most current therapies only addressing symptoms rather than the underlying causes of cognitive decline. NeuroEM Therapeutics is pioneering Transcranial Electromagnetic Treatment using Radio Frequencies (TEMT-RF) as a potentially groundbreaking approach to treating the disease at its root.
The wearable device delivers electromagnetic waves similar to those produced by cell phone signals from multiple emitters. It is being investigated for its potential to break apart toxic protein oligomers within neurons throughout the brain. These oligomers—clusters of beta-amyloid and tau proteins—are thought to drive the progression of Alzheimer's disease. By disrupting these harmful accumulations, TEMT-RF may help restore neuronal function and slow cognitive decline.
"We all know friends and family members who have been impacted by Alzheimer's or dementia," said Peter Bechtel, CEO of CareONE Concierge. "This study represents a potential turning point in the fight against these devastating conditions. By participating in this study, individuals have the opportunity to experience cutting-edge, non-drug therapy while contributing to groundbreaking advancements in Alzheimer's treatment."
This study is independently conducted by CareONE Concierge and is designed for individuals with mild to moderate Alzheimer's-related dementia. Participants will be required to wear the device twice daily for one hour, follow a structured research protocol and complete cognitive assessments throughout the study.
"Our research has shown that TEMT-RF has the potential to impact the key biological processes associated with Alzheimer's disease," said Edward Goodwin, chief scientist at NeuroEM. "This study will help us gather more real-world data on how the device affects cognitive function and overall brain health."
"NeuroEM is excited to partner with CareONE Concierge," stated Chuck Papageorgiou, CEO of NeuroEM Therapeutics. "Our objective is to promote safe, effective and non-invasive technologies for cognitive health, and research initiatives like this are essential in helping us uncover the full potential of TEMT-RF. With Alzheimer's cases increasing, innovative research such as this provides new hope for patients, caregivers and the future of cognitive health. Together, we can take meaningful steps toward a future where memory loss is no longer an inevitable part of aging."
For more information or to apply, email CT@careone-concierge.com or apply at bestmindforme.com.